Latest Healthcare It News

Nanoveu, via its subsidiary EMASS, has expanded its U.S. sales network with key manufacturer representatives to fast-track adoption of its ECS-DoT ultra-low power Edge AI chip across critical OEM hubs.

Ansell Limited reported record FY25 sales and EBIT margins, completing KBU integration ahead of schedule and upgrading synergy targets. The company guides higher adjusted EPS for FY26, fully offsetting US tariff hikes through pricing.

Ansell Limited reports robust FY25 growth driven by strong Industrial and Healthcare segments, completes KBU acquisition integration ahead of schedule, and announces a $200 million share buyback for FY26.

Ansell Limited has announced an unfranked ordinary dividend of USD 0.28 per share for the six months ending June 2025, accompanied by a Dividend Reinvestment Plan available to select shareholders.

Ansell Limited reported robust FY25 results, driven by strong organic growth and the successful integration of Kimberly-Clark’s PPE business. The company also advanced its sustainability commitments and navigated tariff challenges with strategic pricing and sourcing.

Perpetual Credit Income Trust reported a 20.7% increase in net assets to $532.8 million for FY25, while posting a modest profit decline amid challenging market conditions. The Trust’s $93 million capital raise and diversified credit portfolio underpin its strategy for stable income and growth.

Universal Biosensors Inc. has been suspended from ASX trading following the appointment of voluntary administrators, highlighting serious financial distress within the company.

The ASX has suspended the securities of 36 companies for failing to pay their annual listing fees by the August 21 deadline, with a looming delisting threat if fees remain unpaid by August 28.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Nyrada Inc. reported a sharp 25% decline in revenues alongside a 248% surge in net losses for the fiscal year ending June 2025, signaling mounting financial pressures for the pharmaceutical developer.

Monash IVF Group reported a 5.6% rise in underlying EBITDA for FY25, navigating a declining Australian IVF market and operational challenges. The company sets a cautious FY26 NPAT guidance of $20-23 million while focusing on regaining market leadership and implementing safety reforms.

Monash IVF Group reported steady FY25 financial results with revenue and EBITDA growth, while managing clinical incidents and a CEO transition. The company outlines cautious FY26 guidance amid industry headwinds.